NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has inked a cardiac point-of-care diagnostics alliance in China with Lepu Medical Technology, a medical device firm based in Beijing.

Under the deal, Lepu will market in China Qiagen's ESEQuant Lateral Flow System with five cardiac marker tests developed by Lepu intended to diagnose acute myocardial infarction. According to Qiagen, the system will be used in emergency rooms and the tests will be able to provide an accurate diagnosis within minutes at the point of care

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.